Background: Clinical and laboratory criteria are not reliable predictors of deceased donor
Introduction
Liver transplantation is the standard treatment for end-stage liver disease. Although the number of transplant candidates continues to grow, organ availability has plateaued resulting in increasing waitlist mortality [1] . The donor pool has been modestly expanded through increasingly aggressive organ utilization: the use of living donors, deceased donor split livers, and "extended criteria donors." Each opportunity for transplantation of every organ of all donors is thoroughly evaluated by each and every organ procurement organization (OPO) and transplant center. Used judiciously, these grafts provide an opportunity to address the shortage but not without costs. The use of extended criteria grafts predispose recipients to poor initial graft function and increased longterm risk [2] ; the use of living and deceased donor split livers is associated with increased biliary and arterial complications [3e5] . Optimizing the use of these grafts while minimizing recipient risk requires accurate and reproducible assessment of graft quality. Quantitative descriptions of organ quality have yielded specific and accurate relative risks of graft failure for kidney donors [6] . This information has facilitated discussions among donor organizations, transplant surgeons, and even recipients. Similar methodology for liver grafts, namely the donor risk index (DRI), has been less accepted and infrequently used [7] . Standard clinical and laboratory criteria are not reliable predictors. Routine biopsy of donor livers is plagued by risk of injury to the graft, lack of uniformity and availability of microscopic interpretation, and increased cost and delay. Therefore, the gold standard remains physical assessment by transplant surgeons [8] . This, however, leads to inefficient use of resources, by having surgeons evaluate either too many livers only some of which are suitable for transplantation or too few livers, thus forgoing useable grafts. Furthermore, as regional sharing is becoming standard, centers will face increasing difficulties in having their own procurement teams assess all offered grafts. This means relying on surgeons from other centers to make graft suitability determinations, a prospect that makes many ill at ease.
Factors that have previously been shown to affect graft utilization and function include advanced donor age, hypernatremia, prolonged warm ischemia time, vasopressor requirement, and donation after cardiac death [9] . What is needed is a low cost, portable, rapid, noninvasive, standardized, quantitative measure of liver function performed before graft procurement. This study evaluates just such a technique that takes advantage of indocyanine green clearance by hepatocytes.
Indocyanine green clearance is a well-established quantitative test of liver function, used primarily before planning a liver resection [10e12] . A few previous studies have examined the role of indocyanine green clearance in the setting of liver transplantation. Wesslau et al. [13] assessed indocyanine green plasma disappearance rates (ICG-PDR) in donors and its association with graft utilization and function.
Koneru et al. similarly tested ICG-PDR to predict graft function after transplant [14] . Both groups were handicapped by the fact that to measure ICG-PDR, they either had to use an invasive device or draw serial plasma samples and measure the level of ICG at each time point, a time-and resourceintensive process. We now have the distinct advantage of having access to a simple portable device that can easily perform a noninvasive rapid measurement of ICG clearance with minimal set up and training. 
Materials and methods

Patient population and design
Consecutive adult brain-dead donors in a large urban donation service area whose livers were offered to recipients at our center were enrolled in the study with signed informed consent, provided donor research consent was also available. We excluded split liver and donation after cardiac death grafts to minimize variability not strictly due to liver function. All available donor data were collected before procurement. These data included age, gender, race and/or ethnicity, cause of death, length of hospitalization, height, weight, number of vasopressors, history of diabetes, hypertension, substance abuse, hepatitis B and C serology, downtime, vital signs, and laboratory values at presentation, peak, and procurement (Table 1) . At the donor hospital, immediately before organ procurement, ICG-PDR was measured using the noninvasive liver function monitoring system, LiMON (PULSION Medical Systems, Munich, Germany). LiMON measures ICG clearance by noninvasive pulse-densitometry. Injected ICG is detected from fractional pulsatile changes in optical absorption. This allows for continuous and repeated measurements of ICG-PDR. Two liver transplant perfusionists trained in using the device carried the device and ICG with them to the site of organ procurement. An ICG finger clip placed on the donor was connected to a liver function monitor. A dose of 0.25 mg/ kg ICG was given through a central or peripheral vein as a bolus and immediately flushed with 10 mL of normal saline [15] . ICG-PDR measurements were automatically performed by the monitor. Both donor and recipient surgeons were blinded to ICG-PDR measurements. The transplant team made an independent decision of whether to transplant the graft. After transplantation, the function of the allograft was evaluated using standard laboratory criteria of the recipient. For patients transplanted at the primary center, values of international normalized ratio (INR), serum bilirubin, lactate dehydrogenase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were recorded up to postoperative day 30; patient and graft survival were also recorded for 1 y. For patients transplanted at backup centers, only 7-and 30-d graft survivals were available. This study was reviewed and approved by the University of California, Los Angeles, Institutional Review Board and the local OPO OneLegacy Research Review Board.
Statistical analysis
Descriptive statistics were used to describe study samples. The chi-square test was used to assess association between categorical variable. Box plot, scatter plot, and histogram were displayed to graphically show the distribution of ICG-PDR. Univariate logistic regression analysis was used to examine the association between covariates and the outcome variable (status of graft). This was further used to generate an receiver operating characteristic (ROC) curve. The covariates that had a P value <0.2 in the univariate analysis were included in the multivariate logistic regression analysis, and forward selection and backward elimination method was used in finding the best 
parsimonious final model. We examined the relationship between the donor variables and 7-and 30-d graft survival or postoperative markers of early graft dysfunction [16] , specifically bilirubin !10 mg/dL or INR ! 1.6 on post-operative day 7, or ALT or AST ! 2000 within the first 7 d. A P value of <0.05 was considered statistically significant. Subjects for whom the ICG-PDR values were unobtainable were excluded from the statistical analysis. All statistical analyses were conducted using JMP, version 9 (SAS Institute Inc, Cary, NC).
Results
ICG clearance
ICG-PDR measurements were performed on 53 consecutive donors for 51 potential recipients. The recorded donor and recipient variables are listed in Table 1 . Some demographic data of donors and recipients are listed in Tables 2 and 3 . Measurement of ICG-PDR took an average of 14 min to perform (range, 9e24 min) from the time the patient was placed on the operating table to the time the ICG-PDR value was obtained (Fig. 1 ). Values were not obtained (i.e., the device did not give a reading) for three cases, two in organs that were transplanted and one in an organ that was not transplanted. This was likely due to severe vasoconstriction from vasopressors in one donor, false nails in another donor, and for undetermined reasons in the remaining donor. The ICG-PDR values in the study population, 22.5 AE 6.8% per min, match well with what is reported in the literature for normal individuals [17] (Fig. 2A) . Linear fit of the variables shows that ICG-PDR decreases with the age of the donor (Fig. 2B) . No other donor variables, including medical history, mechanism of death, and laboratory values at admission, peak, or procurement, were significantly associated with ICG-PDR. For example, there was no association with gender, height, 
weight, body mass index, ALT, AST, bilirubin, INR, number of vasopressors, or blood gas chemistry. Furthermore, there was no association with either total or macrovesicular steatosis on biopsy.
Graft survival
The 51 recipients in this study constituted a representative subset of our general recipient patient population. Their characteristics are listed in Table 3 . Of the 53 donors we examined for them, 14 liver grafts were declined by our center owing to quality and one was declined for size. Of those turned down for quality, six were deemed fibrotic (four by biopsy and two by palpation), four were felt to be too stiff on palpation after cold perfusion (one with 30% steatosis by biopsy), two were too steatotic (50% and 70% macrosteatosis), and two had poor quality arteries. Because all the donors were within our Donor Service Area, cold ischemia time likely did not figure significantly into the decision to use the graft. Of these organs, four were used by a backup center (one that was turned down for size and three that were turned down for quality; Fig. 3 ). Grafts that were not transplanted due to quality were counted as nonsurviving grafts. Thus, the primary surgeon's assessment of the graft at the time of procurement was highly correlated with 7-d survival (P < 0.001). Nevertheless, ICG-PDR was the only donor factor associated with 7-d survival of a liver graft ( Table 4 ). The mean ICG-PDR for grafts surviving 7 d was 24.2% per min and for nonsurviving grafts was 18.7% per min. Using logistic regression, we calculated an ROC curve. Setting the cutoff value of ICG-PDR at 19.3% per min as a predictor of 7-d graft survival maximized specificity and sensitivity with an area under the curve (AUC) of 0.747 (Fig. 4) . Donor Risk Index, donor age, and transaminase levels at peak or procurement were not significantly associated with 7-d graft survival (Table 4) , neither were any recorded recipient factors nor the training level of the procuring surgeon. On multivariate analysis, only ICG-PDR stayed significant with an odds ratio of 1.08 (1.04e1.12; P < 0.0001).
Comparison of ICG-PDR values with graft outcomes
There were four grafts with ICG-PDR values above 19.3% per min that did not survive 7 d (Table 5) . Two of these grafts (ICG-PDR values of 28.3 and 24.9% per min) were deemed good grafts by the procuring surgeon and were used by the primary center. One graft failure was in a patient who underwent a redo liver transplant operation requiring massive transfusions; he died of cardiac failure on postoperative day 2. The second graft failure was in a patient who died of cardiac arrest shortly after reperfusion. These deaths were likely not graft quality related. The remaining two grafts were discarded because the procuring surgeon deemed them too stiff and fibrotic on cold perfusion on inspection in the donor operating room. One had fibrosis on frozen section analysis at the procurement hospital. Likely because of those assessments, the grafts were declined by all backup centers. It is unknowable whether these grafts would have survived had they been used. There were six organs that did survive beyond 7 d despite having an ICG-PDR value <19.3% per min ( Table 5 ). Four of these grafts were used in recipients with physiological Model for End-Stage Liver Disease (MELD) scores of 16, one was used in a status 1a patient, and one (declined by the procuring surgeon) was used in a patient not at the primary center with undisclosed MELD and disease etiology. Of the 14 organs turned down for quality by the procuring surgeon, three were used by a backup center. All those grafts survived >30 d. Two of the grafts had ICG-PDR >19.3% per min.
Discussion
Liver allograft quality varies widely. The ultimate goal of being able to reliably predict risk of graft failure has not yet been achieved. The liver DRI has met with very limited use because of concerns that it does not accurately predict post-transplant survival, excludes relevant donor factors, and that it is too complicated for ease of use [18] . Currently, physician expertise and experience is the dominant determinant of liver graft utilization, something that does not allow for standardization and critical evaluation of how to improve the system. This also limits liver graft portability and sharing among Donor Service Areas and regions. Furthermore, the lack of a reliable means of assessing liver function places much pressure on the OPO to expend a great deal of energy evaluating possibly unusable liver grafts or not evaluating perfectly good grafts. Although transplant surgeons depend greatly on the gross appearance of liver grafts and routine liver function tests obtained during the donor's hospitalization, many studies have shown that these factors are often unreliable and irreproducible [8, 19] . Furthermore, a large amount of money and resources are involved merely to arrange for the operative evaluation of liver grafts.
Our study, too, shows that the donor liver function tests and history do not correlate with ICG clearance, graft utilization, graft survival, and post-transplant graft function. Although several assays to measure the synthetic or clearance capabilities of the liver have been reported in the literature, including lidocaine metabolite clearance [20] , all these assays 
experience being either difficult or time intensive to perform. Previous studies to measure ICG-PDR in liver grafts have been performed, although none have been performed to predict graft survival [13, 14] . All these studies have been limited technically by the inability to perform this assay quickly in the donor hospital. Increasingly, frozen section histologic examination of grafts before implantation is being used, looking for microscopic features of steatosis, fibrosis, necrosis, and inflammation [21] .
A simple reproducible quantitation of the risk of liver graft failure would immensely help OPOs triage possible donors and aid transplant physicians in deciding whether to use an organ and also in discussing with their patients the suitability of offered organs. Here, we report the successful use of a portable quantitative means of assessing liver function and its association with graft survival. This test can be performed easily and routinely, at the bedside by nurses and perfusionists from the procurement team and also by OPO personnel before organ offers are made.
Although it is possible that this study was not adequately powered strictly to address this question, our findings further validate the widely held notion that no single commonly used donor history, laboratory value, or index (DRI, age, liver function tests, and so forth) correlates with graft survival or utilization. There are likely multiple interrelated donor factors, not to mention recipient factors, that make predicting graft utilization and donorerecipient matching difficult. A quantitative measure of graft function validated by a larger study with a wider variety of donors and recipients is necessary to better address that question and would facilitate grafterecipient matching.
The fact that the procuring surgeon was superior to ICG-PDR measurement in predicting graft survival is at least partially due to the inherent bias of the study, as they are the established gold standard and that in this blinded study, the ICG-PDR measurement did not affect whether a graft was discarded or used. It is also likely that surgeon assessment is quite good at minimizing poor outcomes. However, we cannot standardize surgeon assessments and we cannot even obtain such an assessment without taking the donor to the operating room and doing the procurement operation. It is unknown whether we can increase utilization by providing a quantitative means of measuring liver function. It is possible that a validated preprocurement assessment of donor liver graft function would alter the number or improve the selection of potential liver donors, leading to greater efficiency. It is also possible that ICG-PDR cutoff values may be derived to match graft quality to recipient severity of illness.
These data warrant further exploration in a larger trial in a variety of settings to evaluate acceptable values for donated livers. At a time of increasing regional sharing and calls for national organ sharing, this method would assist in the 
standardization of graft evaluation. It could also lead to increasing liver graft utilization while decreasing travel risk and expense.
